• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

供者类型对成熟淋巴细胞恶性肿瘤减低强度预处理异基因造血干细胞移植的影响。

Impact of donor types on reduced-intensity conditioning allogeneic stem cell transplant for mature lymphoid malignancies.

机构信息

Department of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.

Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

出版信息

Bone Marrow Transplant. 2022 Feb;57(2):243-251. doi: 10.1038/s41409-021-01525-1. Epub 2021 Nov 24.

DOI:10.1038/s41409-021-01525-1
PMID:34815519
Abstract

We retrospectively compared the outcomes of reduced-intensity conditioning (RIC) transplantation from matched related donors (MRD; n = 266), matched unrelated donors (MUD; n = 277), and umbilical cord blood (UCB; n = 513) for mature lymphoid malignancies. The 3-year overall survival rates for the MRD, MUD, and UCB groups were 54%, 59%, and 40%, respectively (P < 0.001). Multivariate analysis showed no differences in survival between the MRD group and the MUD or UCB group. However, survival was significantly affected by the conditioning regimen and graft-versus-host disease (GVHD) prophylaxis in the UCB group, but not in the MRD and MUD groups. Notably, multivariate analysis showed that the risk of overall mortality in the UCB recipients who received the optimal conditioning regimen and GVHD prophylaxis (n = 116) was lower than that in the MRD group (relative risk [RR], 0.69; P = 0.03) and tended to be lower than that in the MUD group (RR, 0.75; P = 0.09). Our results suggest that UCB transplantation performed with the optimal conditioning regimen and GVHD prophylaxis is highly effective. Moreover, UCB is readily available. Thus, UCB transplantation with the optimal conditioning regimen and GVHD prophylaxis is preferable to MUD transplantation when MRD are not available in the setting of RIC transplantation for mature lymphoid malignancies.

摘要

我们回顾性比较了三种不同来源的造血干细胞移植治疗成熟淋巴细胞恶性肿瘤的结果

亲缘全相合供者(MRD;n=266)、亲缘不全相合供者(MUD;n=277)和脐带血(UCB;n=513)。MRD、MUD 和 UCB 组的 3 年总生存率分别为 54%、59%和 40%(P<0.001)。多因素分析显示,MRD 组与 MUD 组或 UCB 组的生存无差异。然而,在 UCB 组中,生存受移植前预处理方案和移植物抗宿主病(GVHD)预防方案的影响,而在 MRD 和 MUD 组中则没有影响。值得注意的是,多因素分析显示,接受最佳预处理方案和 GVHD 预防方案的 UCB 移植受者(n=116)的总死亡率风险低于 MRD 组(相对风险 [RR],0.69;P=0.03),且倾向于低于 MUD 组(RR,0.75;P=0.09)。我们的研究结果表明,采用最佳预处理方案和 GVHD 预防方案的 UCB 移植具有较高的疗效。此外,UCB 来源广泛。因此,在接受成熟淋巴细胞恶性肿瘤的 RIC 移植治疗时,如果无法获得 MRD,与 MUD 移植相比,UCB 移植联合最佳预处理方案和 GVHD 预防方案更为可取。

相似文献

1
Impact of donor types on reduced-intensity conditioning allogeneic stem cell transplant for mature lymphoid malignancies.供者类型对成熟淋巴细胞恶性肿瘤减低强度预处理异基因造血干细胞移植的影响。
Bone Marrow Transplant. 2022 Feb;57(2):243-251. doi: 10.1038/s41409-021-01525-1. Epub 2021 Nov 24.
2
Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.与匹配的相关或无关供体移植相比,高危急性髓系白血病患者在脐血移植前采用非清髓性预处理方案的预后较差。
Biol Blood Marrow Transplant. 2014 Oct;20(10):1560-5. doi: 10.1016/j.bbmt.2014.06.006. Epub 2014 Jun 14.
3
Effect of graft source on unrelated donor hemopoietic stem cell transplantation in adults with acute myeloid leukemia after reduced-intensity or nonmyeloablative conditioning: a study from the Société Francaise de Greffe de Moelle et de Thérapie Cellulaire.移植物来源对接受减低强度或非清髓性预处理的成年急性髓系白血病患者无关供者造血干细胞移植的影响:来自法国骨髓移植与细胞治疗协会的一项研究
Biol Blood Marrow Transplant. 2015 Jun;21(6):1059-67. doi: 10.1016/j.bbmt.2015.02.014. Epub 2015 Feb 20.
4
Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with Hematologic Malignancies.血液恶性肿瘤患者脐带血移植与匹配相关或匹配无关供者移植后 1 年生存率的降低。
Transplant Cell Ther. 2021 Aug;27(8):669.e1-669.e8. doi: 10.1016/j.jtct.2021.05.002. Epub 2021 May 12.
5
Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor.55岁以上患者的减低强度异基因移植:对于没有匹配的相关供者的患者,无关脐血是安全有效的。
Biol Blood Marrow Transplant. 2008 Mar;14(3):282-9. doi: 10.1016/j.bbmt.2007.12.488.
6
Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.与其他替代供体和匹配的同胞移植物相比,未处理的单倍体同基因移植。
Biol Blood Marrow Transplant. 2014 Oct;20(10):1573-9. doi: 10.1016/j.bbmt.2014.05.029. Epub 2014 Jun 5.
7
Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.低剂量抗胸腺细胞球蛋白预防亲缘全相合异基因造血干细胞移植后移植物抗宿主病
Biol Blood Marrow Transplant. 2017 Dec;23(12):2096-2101. doi: 10.1016/j.bbmt.2017.08.007. Epub 2017 Aug 15.
8
Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies.采用阿仑单抗的减低强度异基因移植,供者为 HLA 匹配的亲缘、非亲缘或单倍体相合亲缘供者,用于血液系统恶性肿瘤患者。
Biol Blood Marrow Transplant. 2014 Feb;20(2):257-63. doi: 10.1016/j.bbmt.2013.11.010. Epub 2013 Nov 20.
9
The long-term outcome of reduced-intensity allogeneic stem cell transplantation from a matched related or unrelated donor, or haploidentical family donor in patients with leukemia: a retrospective analysis of data from the China RIC Cooperative Group.白血病患者接受来自匹配的相关或无关供体或单倍体相合家族供体的低强度异基因干细胞移植的长期结局:中国低强度移植协作组数据的回顾性分析
Ann Hematol. 2017 Feb;96(2):279-288. doi: 10.1007/s00277-016-2864-y. Epub 2016 Nov 18.
10
Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation.与匹配的亲缘供者相比,使用匹配的无关供者与降低强度预处理的造血干细胞移植后较低的复发率和更好的无进展生存相关。
Biol Blood Marrow Transplant. 2011 Aug;17(8):1196-204. doi: 10.1016/j.bbmt.2010.12.702. Epub 2010 Dec 27.

引用本文的文献

1
Machine Learning Algorithm to Explore Patients With Heterogeneous Treatment Effects of Clinically Significant CMV Infection and Non-Relapse Mortality After HSCT.探索异质性治疗效果的HSCT后具有临床意义的巨细胞病毒感染和非复发死亡率患者的机器学习算法
EJHaem. 2025 Aug 9;6(4):e70117. doi: 10.1002/jha2.70117. eCollection 2025 Aug.
2
T-cell Large Granular Lymphocytic Leukemia with a STAT3 Mutation Successfully Treated with Cord Blood Transplantation.伴有STAT3突变的T细胞大颗粒淋巴细胞白血病经脐血移植成功治愈
Intern Med. 2025 Feb 1;64(3):449-454. doi: 10.2169/internalmedicine.4076-24. Epub 2024 Aug 28.
3
Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma.

本文引用的文献

1
Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial.双份无关脐血与 HLA 单倍体相合骨髓移植:BMT CTN 1101 试验。
Blood. 2021 Jan 21;137(3):420-428. doi: 10.1182/blood.2020007535.
2
Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant.成人脐带血移植的总生存率与匹配相关移植相当,且 GRFS 改善。
Blood Adv. 2020 May 26;4(10):2227-2235. doi: 10.1182/bloodadvances.2020001554.
3
Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR.
B细胞淋巴瘤中CAR T细胞治疗后复发的治疗策略。
Front Pediatr. 2024 Jan 12;11:1305657. doi: 10.3389/fped.2023.1305657. eCollection 2023.
非清髓性供者移植治疗霍奇金和非霍奇金淋巴瘤:来自 LWP-EBMT、Eurocord 和 CIBMTR。
J Clin Oncol. 2020 May 10;38(14):1518-1526. doi: 10.1200/JCO.19.02408. Epub 2020 Feb 7.
4
PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.基于 PTCy 的单倍体相合与匹配相关或无关供者减低强度预处理移植治疗弥漫性大 B 细胞淋巴瘤。
Blood Adv. 2019 Feb 12;3(3):360-369. doi: 10.1182/bloodadvances.2018027748.
5
Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine.与单份脐带血移植相比,单倍体相合移植与更好的总体生存相关:一项使用噻替哌、白消安和氟达拉滨预处理的急性白血病患者的 EBMT-Eurocord 研究。
J Hematol Oncol. 2018 Aug 30;11(1):110. doi: 10.1186/s13045-018-0655-8.
6
Transplant strategies in relapsed/refractory Hodgkin lymphoma.复发/难治性霍奇金淋巴瘤的移植策略。
Blood. 2018 Apr 12;131(15):1689-1697. doi: 10.1182/blood-2017-09-772673. Epub 2018 Mar 2.
7
Occurrence of graft-versus-host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT.脐带血移植治疗急性髓系白血病后移植物抗宿主病的发生增加了死亡率:来自 Eurocord 和 EBMT 的 ALWP 的报告。
J Intern Med. 2018 Feb;283(2):178-189. doi: 10.1111/joim.12696. Epub 2017 Nov 6.
8
Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.移植后环磷酰胺为基础的单倍体相合移植作为霍奇金淋巴瘤同胞或无关供者移植的替代方案:欧洲血液和骨髓移植学会淋巴瘤工作组的注册研究。
J Clin Oncol. 2017 Oct 20;35(30):3425-3432. doi: 10.1200/JCO.2017.72.6869. Epub 2017 Aug 28.
9
Impact of graft-versus-host disease on outcomes after unrelated cord blood transplantation.异基因造血干细胞移植后移植物抗宿主病对结局的影响。
Leukemia. 2017 Mar;31(3):663-668. doi: 10.1038/leu.2016.288. Epub 2016 Oct 17.
10
Cord-Blood Transplantation in Patients with Minimal Residual Disease.微小残留病患者的脐血移植
N Engl J Med. 2016 Sep 8;375(10):944-53. doi: 10.1056/NEJMoa1602074.